Integrated Micro-Chromatography Systems

IMCS has established itself as a provider of specialized tools for sample preparation and analysis in life sciences and diagnostics. Its technology platform centers on two main pillars: genetically engineered beta-glucuronidase enzymes (IMCSzyme®) for hydrolyzing drug metabolites and a patented, automated dispersive solid-phase extraction system (IMCStips®) for high-throughput protein and biomolecule purification. The company leverages this expertise to address bottlenecks in proteomics and glycan research, with leadership experienced in forensic toxicology and enzyme engineering. IMCS appears to be a commercial-stage, revenue-generating private company targeting research and clinical laboratory customers.

Patented automated dispersive solid-phase extraction technology (IMCStips®) for high-throughput biomolecule purification and a collection of genetically modified pure beta-glucuronidase enzymes (IMCSzyme®) for sample hydrolysis.

IMCS competes in the sample preparation segment against giants like Thermo Fisher, Agilent, and Waters, as well as numerous specialty players. Its differentiation lies in the patented dispersive resin tip design for automation and specialized, high-efficiency recombinant enzymes for hydrolysis, targeting specific workflow bottlenecks.